Cumulus and Transpharmation Link Preclinical and Clinical EEG Data

Central nervous system drug development currently faces a 6.7% success rate, often hindered by a sharp discontinuity in how brain function is measured. In preclinical stages, researchers rely on controlled electrophysiological data, but once trials move to humans, metrics typically shift to subjective symptom scales. This transition often leaves sponsors unable to determine if a failed study resulted from poor methodology, inadequate exposure, or an unsuitable patient population.

To address this, the partnership enables biopharma sponsors to design preclinical EEG packages that directly mirror the NeuLogiq platform’s clinical and home-based assessments. This allows for a consistent physiological readout, such as the conserved EEG signatures for ketamine observed in mouse, rat, dog, and human models. By standardizing these markers, developers can track target engagement from the laboratory into early-phase clinical testing without the traditional data break at the species boundary.